Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers

NCT05758545 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device through 24 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.

Conditions Studied

Interventions

  • DEVICE Sham device
  • DEVICE COMS One device

Study Locations (20)

California

  • Center for Clinical Research Inc. — Castro Valley
  • VA Central California Healthcare — Fresno
  • Limb Preservation Platform, Inc. — Fresno
  • Angel City Research, Inc. — Los Angeles
  • UCLA Ronald Regan - Department of Surgery — Los Angeles
  • Center for Clinical Research Inc. — San Francisco
  • Center for Clinical Research Inc. — San Francisco
  • ILD Research Center — Vista

Florida

  • Bay Pines VA Healthcare System — Bay Pines
  • MCR Health — Bradenton
  • University of Florida Health Jacksonville — Jacksonville
  • Clever Medical Research LLC — Miami
  • The Angel Medical Research Corporation — Miami Lakes
  • Vital Medical Research — Sweetwater

Illinois

  • Northwestern University Feinberg School of Medicine — Chicago
  • Rush University — Chicago
  • Gateway Clinical Trials — O'Fallon

Arizona

  • Titan Clinical Research — Mesa
  • Southern Arizona VA Health Care System — Tucson

Georgia

  • Aiyan Diabetes Center — Augusta

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2023-06-19
Est. Completion 2027-06-19
Phase NA

Sponsor

Piomic Medical

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05758545

The ClinicalTrials.gov registry entry for NCT05758545 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Piomic Medical, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions — of which Sham device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05758545 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05758545 about?

NCT05758545 is a clinical study titled "Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers". The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure ...

What is the current status of trial NCT05758545?

This trial is currently recruiting. It is a NA study. The enrollment target is 450 participants. The study started on 2023-06-19. Estimated completion is 2027-06-19.

What conditions does trial NCT05758545 study?

This clinical trial studies the following conditions: Diabetic Foot Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05758545?

The interventions under investigation include: Sham device (DEVICE), COMS One device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05758545?

This trial is sponsored by Piomic Medical, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05758545 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial